POB 14/ 6. 950 patienter (0, 2%) for lumiracoxib mod 64/ 6. 968 patienter (0, 92%) for NSAID, med et risikoforhold (RF) på 0, 21 [95% konfidensinterval (KI) 0, 12- 0, 37] p < 0, 0001
(0.2%) for lumiracoxib versus 64/ 6968 patients (0.92%) for NSAIDs, with a hazard ratio (HR) of 0.21 [95% CI 0.12-0.37] p < 0.0001.